Where Do Recent Small Molecule Clinical Development Candidates Come From?
- PMID: 29920198
- DOI: 10.1021/acs.jmedchem.8b00675
Where Do Recent Small Molecule Clinical Development Candidates Come From?
Abstract
An analysis of 66 published clinical candidates from Journal of Medicinal Chemistry has been conducted to shed light on which lead generation strategies are most frequently employed in identifying drug candidates. The most frequent lead generation strategy (producing a drug candidate) was based on starting points derived from previously known compounds (43%) followed by random high throughput screening (29%). The remainder of approaches included focused screening, structure-based drug design (SBDD), fragment-based lead generation (FBLG), and DNA-encoded library screening (DEL). An analysis of physicochemical properties on the hit-to-clinical pairs shows an average increase in molecular weight (ΔMW = +85) but no change in lipophilicity (ΔclogP = -0.2), although exceptions are noted. The majority (>50%) of clinical candidates were found to be structurally very different from their starting point and were more complex. Finally, several reports of noncovalent scaffolds modified by a covalent warhead using SBDD approaches are discussed.
Similar articles
-
From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery.Curr Top Med Chem. 2017;17(20):2260-2270. doi: 10.2174/1568026617666170224113437. Curr Top Med Chem. 2017. PMID: 28240184 Review.
-
Targeting cancer using fragment based drug discovery.Anticancer Agents Med Chem. 2012 Jan;12(1):40-8. doi: 10.2174/187152012798764660. Anticancer Agents Med Chem. 2012. PMID: 21707503
-
Covalent fragment libraries in drug discovery.Drug Discov Today. 2020 Jun;25(6):983-996. doi: 10.1016/j.drudis.2020.03.016. Epub 2020 Apr 13. Drug Discov Today. 2020. PMID: 32298798 Review.
-
An Analysis of Successful Hit-to-Clinical Candidate Pairs.J Med Chem. 2023 Jun 8;66(11):7101-7139. doi: 10.1021/acs.jmedchem.3c00521. Epub 2023 May 24. J Med Chem. 2023. PMID: 37224022 Review.
-
From fragment screening to potent binders: strategies for fragment-to-lead evolution.Mini Rev Med Chem. 2009 Jul;9(8):956-61. doi: 10.2174/138955709788681645. Mini Rev Med Chem. 2009. PMID: 19601891 Review.
Cited by
-
What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications.J Med Chem. 2021 Apr 22;64(8):4410-4429. doi: 10.1021/acs.jmedchem.1c00181. Epub 2021 Apr 13. J Med Chem. 2021. PMID: 33847110 Free PMC article. Review.
-
Conjugation as a Tool in Therapeutics: Role of Amino Acids/Peptides-Bioactive (Including Heterocycles) Hybrid Molecules in Treating Infectious Diseases.Antibiotics (Basel). 2023 Mar 7;12(3):532. doi: 10.3390/antibiotics12030532. Antibiotics (Basel). 2023. PMID: 36978399 Free PMC article. Review.
-
The Time and Place for Nature in Drug Discovery.JACS Au. 2022 Oct 14;2(11):2400-2416. doi: 10.1021/jacsau.2c00415. eCollection 2022 Nov 28. JACS Au. 2022. PMID: 36465532 Free PMC article. Review.
-
Limonin as a Starting Point for the Construction of Compounds with High Scaffold Diversity.Angew Chem Int Ed Engl. 2021 Jul 12;60(29):16119-16128. doi: 10.1002/anie.202104228. Epub 2021 Jun 10. Angew Chem Int Ed Engl. 2021. PMID: 33973348 Free PMC article.
-
Fragment-pair based drug molecule solubility prediction through attention mechanism.Front Pharmacol. 2023 Oct 10;14:1255181. doi: 10.3389/fphar.2023.1255181. eCollection 2023. Front Pharmacol. 2023. PMID: 37881183 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources